The Cabinet's Media Center released a video showcasing the "Gypto Pharma" drug city as a key national project. The initiative reflects a broader push to localize advanced industrial and technological capabilities, ensuring the availability of safe and effective medicine at stable prices.
Dr. Hossam Abdel Ghaffar, the spokesperson for the Ministry
of Health and Population, stated that President Abdel Fattah El-Sisi has issued
a sustained directive to localize the production of medicines and medical
supplies.
He explained that the ministry has a clear strategy to
implement these presidential mandates, starting with upgrading the
infrastructure of pharmaceutical factories. He noted that the number of
factories has grown by approximately 30% to 170, up from 130 in 2015, alongside
the establishment of specialized facilities for specific drugs.
The state is also forging partnerships with international
companies to localize the production of highly complex drugs that require
advanced technology. He said this effort has led to the domestic production of
over 50 generic versions of essential medications.
Dr. Amr Mamdouh, the managing director of Gypto Pharma,
emphasized that the drug city is a national project born from the political
leadership's vision to build a modern pharmaceutical hub. He said the facility
uses the latest technology and adheres to all global quality standards to
ensure citizens can access safe, effective, and affordable medicine.
He added that the city embodies the state's efforts to
localize the pharmaceutical industry, which helps reduce import costs and
provides high-quality drugs that rival international standards, bolstering
public trust in local products.
Mamdouh confirmed that the company focuses on producing
drugs for common chronic diseases like diabetes, hypertension, and heart and
digestive system ailments. He said Gypto Pharma has launched about 100 new
products in the last four years and aims to increase that number to 200 within
the next three years.
Achieving a high-quality drug, he said, involves a long
process that begins with research and development, followed by selecting the
best raw materials, conducting laboratory tests and clinical studies, and
performing stability tests. The process concludes with manufacturing using
modern technology and rigorous quality control.
Dr. Aalia El-Mestkawy, head of the technical sector at Gypto
Pharma, noted that the city's capabilities cover all forms of pharmaceutical
production, adhering to the highest global quality standards. She highlighted
its vital role in localizing drug production and ensuring a safe, effective,
and affordable supply.
Dr. Mahmoud Heidar, head of production at Gypto Pharma, said
the company uses the latest international production lines, managed by a
skilled and qualified team, to ensure product safety and quality.
Dr. Mahmoud Khallaf, head of quality control at Gypto
Pharma, stated that the company's primary goal is to build quality into every
drug, from the initial raw materials to the final product, to guarantee a safe
and effective medication.
Dr. Ibrahim El-Shafei, manager of solid product
manufacturing, added that Gypto Pharma possesses all the advanced capabilities
necessary to produce drugs that meet global quality standards.
The video also showed that the drug city is committed to
improving the quality of its products through multiple stages, starting with
the research and development department, which selects the best raw materials
and subjects them to precise scientific experiments.
The company's focus extends beyond conventional products to include the production of highly accurate and specialized biological drugs.